A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
Completed · Phase 2
Conditions studied: Graves' Disease
In brief
An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
Key facts
- Study ID
- NCT02713256
- Run by
- Novartis Pharmaceuticals
- People needed
- 15
- Starts
- 2016-04-19
- Expected to finish
- 2017-04-24
- Last updated by the study team
- 2021-01-05
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Honolulu, Hawaii, United States
- Novartis Investigative Site — Rochester, Minnesota, United States
- Novartis Investigative Site — Mainz, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.